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More active high-dose chemotherapy (HDC) regimens are needed for refractory Hodgkin’s lymphoma (HL).
We report a cohort analysis of 180 consecutive patients with primary refractory or poor-risk relapsed HL
treated with busulfan-melphalan (Bu-Mel) (n ¼ 39), gemcitabine-busulfan-melphalan (Gem-Bu-Mel)
(n ¼ 84), or BEAM (BCNU, etoposide, ara-C, melphalan; n ¼ 57) between 2005 and 2010. Their pre-HDC
positron emission tomography (PET) scans were interpreted prospectively. Despite more prevalent
poor-risk features in the Gem-Bu-Mel cohort, such as PET-positive tumors at HDC, tumors growing at HDC,
extranodal disease, or bulky tumors at prior relapse, this cohort had improved outcomes compared with the
Bu-Mel and BEAM cohorts, with event-free survival (EFS) rates of 57%, 33%, and 39%, respectively (P ¼ .01), at
median follow-up of the whole population of 36 months (range, 3 to 72). Their respective overall survival (OS)
rates were, respectively, 82%, 52%, and 59% (P ¼ .04). Secondary acute myelogenous leukemia was seen in
5 patients after BEAM but was not seen in Gem-Bu-Mel and Bu-Mel cohorts (P ¼ .004). Multivariate analyses
showed independent adverse effects of an HDC regimen different from Gem-Bu-Mel (hazard ratio [HR] for
EFS ¼ 2.3, P ¼ .0008; HR for OS ¼ 2.7, P ¼ .0005), positive PET at HDC (HR for EFS ¼ 2.2, P ¼ .004, HR for
OS ¼ 3.1, P ¼ .0001), and >1 previous salvage line (HR for EFS ¼ 1.9, P ¼ .008, HR for OS ¼ 1.8, P ¼ .07). Gem-
Bu-Mel improved outcomes in this cohort analysis of patients with refractory/poor-risk relapsed HL and
merits evaluation in randomized phase III trials.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy (HDC) with autologous stem
cell transplant (ASCT) is standard treatment of patients with
relapsed or primary refractory Hodgkin’s lymphoma (HL)
[1,2]. Adverse clinical predictors of post-HDC outcome
include the length of the prior disease-free interval, presence
of B symptoms, extranodal disease or bulky tumors at the
time of relapse or progressive disease (PD), relapse within
a prior radiation ﬁeld, and number of prior salvage lines of
chemotherapy [3-5]. In addition, there is emerging evidence
that persistence of metabolically active tumor in pre-HDC
seen with positron emission tomography (PET) is a major
adverse prognostic factor [6-9]. These last observations come
mostly from retrospective analyses and, therefore, need
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12.10.029BEAM (carmustine, etoposide, cytarabine, and
melphalan) remains the standard HDC combination for HL
despite its suboptimal results in patients with refractory
tumors or poor prognostic features, with long-term event-
free survival (EFS) rates of 30% to 50% and 15% to 40%,
respectively [3-5]. With the goal of improving these results,
since 2005 we have conducted sequential studies of
busulfan-melphalan (Bu-Mel) and gemcitabine-busulfan-
melphalan (Gem-Bu-Mel), enrolling patients with refrac-
tory or poor-prognosis relapsed HL [10,11]. Bu-Mel is an
all-alkylator regimen that achieves a precise systemic
exposure to busulfan through prospective pharmacokinetic
monitoring, which increases its safety and tolerability [10].
The Gem-Bu-Mel combination builds on this construct and
exploits the synergy between gemcitabine and alkylating
agents based on DNA damage repair inhibition [11]. Both
regimens cause a manageable toxicity proﬁle of mucositis
and skin rash and have shown high activity among patients
with non-Hodgkin lymphoma (HL) and HL enrolled in their
trials. All other HL patients receiving an ASCT at our insti-
tution since 2005 have received BEAM. The pre-HDC PET
status of patients with refractory or poor-prognosis relapsed
HL has been prospectively evaluated at our institution since
2005. We report here a cohort outcome comparison of
patients with refractory or poor-prognosis relapsed HLTransplantation.
Table 1
Patient Characteristics (N ¼ 180)
Characteristic N (%) Value
Age, median (range) 32 (17-65)
Male/female 106/74
HDC regimen
Gem-Bu-Mel 84
BEAM 57
Bu-Mel 39
Front-line chemotherapy
ABVD 176 (98%)
Stanford-V 3 (1.5%)
Other 1 (0.5%)
First-line salvage therapy 180
ICE 101 (56%)
ESHAP 54 (30%)
IGEV 25 (14%)
Second-line salvage therapy 78
GND 26 (33%)
IGEV 24 (31%)
ICE 20 (26%)
Other 8 (10%)
Third-line salvage therapy or beyond 45
GND 18 (34%)
IGEV 17 (32%)
ICE 8 (14%)
Other 10 (19%)
Radiation with initial treatment 52 (29%)
First remission
Primary induction failure 86 (48%)
3-6 mo 50 (28%)
6-12 mo 17 (9%)
>12 mo 27 (15%)
Relapse within prior radiation ﬁeld 22 (12%)
Number of salvage regimens, median (range) 1 (1-5)
1 119 (66%)
>1 61 (34%)
Extranodal disease at relapse/PD 72 (40%)
B symptoms at relapse/PD 21 (12%)
Bulky disease at relapse/PD 55 (30%)
PET at HDC 175 (97%)
Negative 106 (62%)
After ﬁrst salvage line 72 (41%)
After second salvage line 25 (15%)
After third salvage line or beyond 9 (5%)
Positive 69 (38%)
After response to ﬁrst salvage 22 (12%)
After response to second salvage or beyond 22 (12%)
No response to prior line 26 (14%)
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2005 and 2010, as well as the prospective prognostic evalu-
ation of their pre-HDC PET status.
METHODS
Patients
Patients subject to this analysis had refractory or poor-risk relapsed HL
deﬁned as (1) primary refractory HL documented histologically, deﬁned as
active disease after front-line chemotherapy or a combined modality
treatment program, or relapse within 3 months of its completion; (2) poor-
risk relapsed HL, deﬁned as that occurring less than 12 months from the end
of front-line chemotherapy or combined modality therapy or with extra-
nodal involvement at the time of relapse; or (3) refractory relapse, deﬁned
as no response to ﬁrst-line salvage therapy. Second or third lines of salvage
chemotherapy were deﬁned as different regimens used to treat persistent or
PD afer a prior line. They did not include additional cycles of a different
regimen given with peripheral blood progenitor cell mobilizing purposes
after a complete response (CR).
Description of Cohorts
Although the Bu-Mel trial (MDA 2004-0190, NCI registration number:
NCT00427765) was open to all patients with relapsed non-HL and HL [10],
this analysis only includes its refractory or poor-risk relapsed HL subsets, as
deﬁned above. Bu-Mel consisted of four daily doses of busulfan targeting an
average daily area under the curve of 5000 mM ∙ min1 or 130 mg/m2/day
and melphalan at 70 mg/m2/day  2.
The succeeding Gem-Bu-Mel study (MDA 2006-0803, NCI registration
number: NCT00410982) was only open to patients with refractory or poor-
risk relapsed HL and non-HL, deﬁned for the former group by the criteria
outlined above [11]. The Gem-Bu-Mel regimen added 2 doses of gemcitabine
at 225 to 2775 mg/m2/day (as part of a dose escalation trial) infused over 15
to 40 minutes at a ﬁxed dose rate of 10mg/m2/min, combined with busulfan
(targeting an average daily area under the curve of 4000 mM ∙ min1 or
105 mg/m2/day) and melphalan (60 mg/m2/day  2). All HL patients
enrolled in this study, 73% of whomwere treated at or within 2 dose levels of
the maximum tolerated dose (2175 to 2775 mg/m2/day), were included in
this analysis.
The sequential Bu-Mel and Gem-Bu-Mel studies shared the same organ
function eligibility criteria [10,11]. These trials enrolled patients from 2005
to 2007 and from 2007 to 2010, respectively. During this time period, all
other HL patients meeting those trials’ criteria of refractory or poor-risk
relapsed disease and other eligibility criteria, but who were not enrolled,
received BEAM off study and were prospectively registered in our depart-
mental database. The reasons for treating these patients with BEAM
included their declination to participate on study, the requirement by their
third-party payer to only cover treatment off study, or during periods
when enrollment to the Gem-Bu-Mel trial was temporarily held for safety
analyses during its dose escalation portion. BEAM consisted of carmustine
(300 mg/m2), etoposide (200 mg/m2 every 12 hours for 8 doses), ara-C
(200 mg/m2 for 4 doses), and melphalan (140 mg/m2). Patients with
relapsed HL receiving BEAM not meeting poor-risk or refractory disease
criteria were excluded. This cohort analysis of Bu-Mel, Gem-Bu-Mel, and
BEAM was approved by the M.D. Anderson Cancer Center Institutional
Review Board (MDA 2010-0859).
Institutional transplantation guidelines for antiemetics; antibacterial,
antifungal, and antiviral prophylaxis; and red blood and platelet trans-
fusions were followed in the 3 cohorts. Speciﬁc supportive care measures in
the Bu-Mel and Gem-Bu-Mel trials were previously described [10,11].
Peripheral blood progenitor cell was infused on day 0. Granulocyte colony-
stimulating factor was administered at 5 mg/kg/day subcutaneously begin-
ning on day þ5 until neutrophil recovery.
Restaging studies were obtained within 30 days before enrollment and
subsequently at 1, 3, and 6 months after SCT and every 6 months thereafter
as feasible. Patients in the three cohorts had pre-HDC PET or computed
tomography scans that were prospectively interpreted as positive (active
tumor) or negative (no active tumor) using mediastinal blood pool activity
as the reference background [12]. Posttransplantation involved ﬁeld radio-
therapy (IFRT) at 30.6 to 41.4 Gy was uniformly considered across the
3 cohorts for lesions greater than 5 cm at the time of HDC or persistently
PET-positive at the 1-month post-HDC evaluation time point.
Statistical Analyses
Overall response rate and CR rates were calculated among patients with
measurable disease at the time of HDC following the usual criteria [13]. EFS
was deﬁned as the time from HDC to either relapse, secondary tumor, or
death, whichever occurred ﬁrst, or to last contact. Overall survival (OS) was
deﬁned as the time fromHDC to death or last contact. Kaplan-Meier survivalcurves were used to estimate unadjusted time-to-event distribution [14].
The log-rank test was used to compare distributions of time-to-event vari-
ables [15]. For the multivariate analyses, which included variables signiﬁ-
cant at the .05 level, hazard ratios (HRs) were estimated from Cox regression
models. The Fisher exact or chi-square tests were used to assess correlations
across prognostic factors and to compare the incidence of secondary
leukemias across the 3 groups. The Wald test was used in testing hypothesis
on covariates. Results from correlation guided the selection of variables in
themultivariate stepwise regression analyses. All calculations used R v2.12.1
and OpenBUGS v3.1.2 rev 668.RESULTS
Between January 2005 and July 2010, we treated 180 HL
patients with primary refractory (n ¼ 86) or poor risk-
relapsed (n ¼ 94) HL with HDC using Bu-Mel (n ¼ 39,
January 2005 to January 2007), Gem-Bu-Mel (n¼ 84, January
2007 to July 2010), or BEAM (n ¼ 57, January 2005 to July
2010) (Table 1). Sixty-one patients additionally met criteria
for refractory relapse as previously described. Median
follow-up of the whole population is 36 months (range, 6 to
84). Previous front-line chemotherapy consisted of ABVD
(doxorubicin-vinblastine-dacarbazine  bleomycin) for
Table 2
Distribution of Prognostic Features among the Cohorts of Refractory HL Patients Treated with Gem-Bu-Mel, Bu-Mel, or BEAM
Gem-Bu-Mel (n ¼ 84) Bu-Mel (n ¼ 39) BEAM (n ¼ 57) P (Gem-Bu-Mel versus Bu-Mel or BEAM)
PET-positive at HDC 51% 28% 27% .001
Tumor growth at HDC 26% 6% 3% <.0001
Extranodal disease at relapse or PD 51% 30% 32% .01
Primary refractory tumor 61% 31% 40% .004
Bulky (>5 cm) tumor at relapse/PD 38% 20% 24% .03
Age, median (range) 32 (19-61) 31 (17-69) 36 (20-63) .7
Prior CR1
<6 mo 83% 75% 82% .2
6-12 mo 5% 10% 13%
>12 mo 12% 15% 5%
No. prior salvage regimens, mean (range) 1.8 (1-5) 1.55 (1.5) 1.5 (1-5) .15
>1 salvage regimens 44% 49% 39% .6
Prior RT 27% 30% 30% .9
Relapse within prior RT ﬁeld 27% 30% 30% .9
B symptoms at relapse/PD 15% 14% 8% .6
Post-HDC IFRT 26% 21% 9% .02
CR1 indicates ﬁrst complete remission; RT, radiation therapy.
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part of a combined modality program, 22 of whom subse-
quently relapsed within the RT ﬁeld. First-line salvage regi-
mens included ICE (ifosfamide-carboplatin-etoposide)
(n ¼ 101), ESHAP (etoposideemethylprednisoloneeara-
Cecisplatin) (n ¼ 54), or IGEV (ifosfamide-gemcitabine-0 10 20 30 40 50 60 70 80
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Table 3
Univariate Analyses
Variable % EFS P % OS P
HDC regimen
Gem-Bu-Mel 57 82
Bu-Mel 33 52
BEAM 39 59
Bu-Mel versus BEAM .6 .7
Gem-Bu-Mel versus other .01 .04
PET at HDC
Negative 55 .0001 78 .00004
Positive 32 49
Tumor growth at HDC
No 50 <.0005 71 .01
Yes 18 52
Disease status at HDC
PET negative 55 .00002 77 .0002
Responsive PET positive 39 53
Unresponsive PET positive 18 48
No. prior salvage regimens
1 59 .0006 77 .04
>1 33 62
No. prior relapses or PD
1 52 .001 71 .04
>1 31 61
B symptoms at relapse/PD
No 48 68
Yes 27 <.05 58 .1
Prior radiotherapy
No 44 .1 66 .1
Yes 52 75
Relapse within a prior radiation
ﬁeld
No 45 68
Yes 52 .4 74 .6
Primary induction failure
No 47 69
Yes 45 .8 67 .6
Bulky tumor at relapse/PD
No 40 65
Yes 49 .3 76 .2
Extranodal disease at relapse/PD
No 48 67
Yes 43 .4 71 .9
Disease-free interval
6 mo 52 .2 71 .4
>6 mo 45 71
12 mo 49 .7 68 .3
>12 mo 45 79
Post-HDC radiotherapy
No 48 68
Yes 37 .3 69 .9
ALC
Pre-HDC
<600/mm3 48 .4 69 .2
600/mm3 43 64
Day 15
<500/mm3 45 .9 65 .9
500/mm3 47 68
Day 30
<1000/mm3 65 .3 65 .9
1000/mm3 68 68
ALC indicates absolute lymphocyte count.
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tumor that was growing.
Eleven patients with low-risk features enrolled in the Bu-
Mel trial were excluded from this analysis. Their outcome
was signiﬁcantly better than the 38 high-risk Bu-Mel
patients (73% versus 33% EFS, P < .05). Likewise, 59 patients
with low-risk HL, who received BEAM during this period,
excluded from this analysis, had superior EFS rates compared
to the 57 high-risk BEAM patients (89% versus 39%, P< .001).There were no treatment-related deaths in any of the
3 cohorts. Five patients developed secondary acute myelog-
enous leukemia at a median 15 months (range, 4 to 46) after
BEAM, versus none in the Gem-Bu-Mel and Bu-Mel cohorts
(P ¼ .004). These 5 patients presented the following cyto-
genetic abnormalities: del(7) (n ¼ 2), inv(16) (n ¼ 1), t(8;21)
(n ¼ 1), and t(3;21)/t(8) (n ¼ 1). All 5 patients died: 4 with
progressive HL and 1with HL in remission. One patient in the
Bu-Mel cohort developed metastatic colorectal cancer at
28 months posttransplantation and is currently receiving
second-line treatment. No secondary tumors have been
observed to date in the Gem-Bu-Mel cohort.
Comparison of Cohorts Receiving Different HDC Regimens
The Gem-Bu-Mel group had signiﬁcantly more patients
with PET-positive tumors at HDC, tumors growing at HDC,
primary refractory disease, extranodal disease, or bulky
tumors at prior relapse or PD (Table 2). The three cohorts
received a similar number of prior salvage lines. There was
bone marrow involvement in 1 Gem-Bu-Mel patient, 2 Bu-
Mel patients, and no BEAM patients. Median follow-up of
the Gem-Bu-Mel, Bu-Mel, and BEAM groups was 32 months
(range, 12 to 68), 36 months (range, 3 to 72), and 49 months
(range, 8 to 66), respectively. The response rates among
patients with measurable tumors after Gem-Bu-Mel,
Bu-Mel, and BEAM were 91%, 67%, and 88%, respectively
(P ¼ .2), with CR rates of 74%, 58%, and 56%, respectively
(P ¼ .16).
Although criteria for consideration of posttransplantation
IFRT were uniform, more Gem-Bu-Mel patients received it
(n ¼ 22, 26% of patients in this cohort) than in the Bu-Mel
(21%) or BEAM groups (9%) (P ¼ .04). Reasons for IFRT in
Gem-Bu-Mel patients included bulky tumors at HDC
(n ¼ 14), persistently post-HDC PET-positive tumors (n ¼ 2),
or both (n ¼ 6). One, 3, and 1 BEAM patients, respectively,
received IFRT for those same reasons. Three, ﬁve, and one Bu-
Mel patients, respectively, received IFRT for those reasons.
Therefore, the higher prevalence of posttransplantation IFRT
for Gem-Bu-Mel patients was explained by more bulky
tumors at HDC in this cohort.
The EFS rates of the Gem-Bu-Mel, Bu-Mel, and BEAM
cohorts were 57%, 33%, and 39%, respectively, with median
EFS times not reached, 13 and 12 months, respectively
(Figure 1A). The Bu-Mel and BEAM groups had similar EFS
rates (P ¼ .6). Therefore, we combined these two cohorts in
a group we named “Bu-Mel þ BEAM” in all other compara-
tive and prognostic analyses. The Gem-Bu-Mel cohort had
signiﬁcantly improved EFS rates compared with the
combined “Bu-Mel þ BEAM” group (57% versus 35%, P ¼ .01,
Figure 1B).
The OS rates of the Gem-Bu-Mel, Bu-Mel, and BEAM
cohorts were 82%, 52%, and 59%, respectively, with median
OS times not reached, 63 and 53 months, respectively
(Figure 1C). The Bu-Mel and BEAM cohorts had similar OS
rates (P ¼ .8). The OS rate of the Gem-Bu-Mel cohort was
superior to that of the combined “Bu-Mel þ BEAM” group
(82% versus 54%, P ¼ .04, Figure 1D).
Prognostic Factor Analyses
In addition to an HDC regimen different from Gem-Bu-
Mel, univariate analyses identiﬁed the following unfavor-
able factors for EFS: PET-positive tumor at HDC (P ¼ .0001),
tumor growth at HDC (P < .0005), disease status at HDC (PET
negative, responsive PET positive, or unresponsive PET
0 10 20 30 40 50 60 70 80
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ili
ty
Bu-Mel + BEAM
CR2
P =  .01
CR3
PR2
PR3 and bey ond
0 10 20 30 40 50 60 70
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ilit
y
1 prior salvage line
>1 prior salvage line
P < .005
Gem-Bu-Mel
0 10 20 30 40 50 60 70
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ilit
y
No prior gemcitabine/
Prior CR to gemcitabine
Prior gemcitabine with no CR
P = .005
Gem-Bu-Mel
0 10 20 30 40 50 60 70
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ilit
y
PET negative
Responsive PET positive
Unresponsive PET positive
P < .0001
Gem-Bu-Mel
0 10 20 30 40 50 60 70 80
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ili
ty
PET negativ e at HDC
PET conv ersion 
Persistent PET positiv e P = .00002
Gem-Bu-Mel
0 10 20 30 40 50 60 70 80
Months post-HDC
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pr
ob
ab
ili
ty
CR2
PR3 and bey ond
CR3
PR2
P = .0002
Gem-Bu-Mel
Figure 2. Prognostic analysis of EFS. (A) PET and disease status at the time of HDC (Gem-Bu-Mel cohort). (B) Number of prior lines of salvage therapy (Gem-Bu-Mel).
(C) Prior exposure/response to gemcitabine (Gem-Bu-Mel). (D) Pre- and post-HDC PET (Gem-Bu-Mel). (E) Disease status at HDC (Gem-Bu-Mel). (F) Disease status at
HDC (combined Bu-Mel þ BEAM group).
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(P ¼ .0006), number of previous episodes of relapse or PD
(P ¼ .002), and B symptoms at relapse (P < .05) (Table 3).
Patients with primary refractory disease had similar EFS
rates to those with relapsed tumors (47% and 45% EFS,
respectively, P ¼ .8). Neither extranodal disease (P ¼ .4) nor
bulky tumors (P ¼ .3) had a signiﬁcant effect on EFS. None of
these other variables correlated with EFS: duration of prior
CR1, age, prior radiotherapy, or relapse within prior radiation
ﬁeld. Administration of post-HDC IFRT did not have an effect
on EFS (P ¼ .3). The absolute lymphocyte count, determinedpre-HDC, day þ15, and day þ30 post-HDC did not correlate
with any outcome parameter at any of those time points.
Likewise, the absolute monocyte count was not associated
with any outcome parameter on any of those time points
(data not shown).
In speciﬁc analyses of the Gem-Bu-Mel cohort, patients
with PET-negative tumors at HDC, responsive PET-positive
tumors, and unresponsive PET-positive tumors (stable
disease or PD to latest salvage therapy) had EFS rates of 55%,
39%, and 18%, respectively (P < .00005, Figure 2A). Patients
with 1 and >1 prior salvage lines had EFS rates of 71% and
Y. Nieto et al. / Biol Blood Marrow Transplant 19 (2013) 410e417 41533%, respectively (P < .005, Figure 2B). Prior treatment with
gemcitabine without achieving a CR (n ¼ 22) was associated
with worse EFS than a prior CR (n¼ 13) or no exposure to this
drug (n ¼ 49) (P ¼ .0003 and P ¼ .0002, respectively,
Figure 2C). The 3 subsets of patients with negative PET at
HDC, PETconversion from positive to negative after HDC, and
a persistently positive PET scan after HDC had signiﬁcantly
different EFS rates (71% versus 47% versus 17%, P ¼ .00002,
Figure 2D), with signiﬁcant differences between the PET-
negative and PET-conversion subsets (P ¼ .01). Disease
status at HDC (CR2, PR2, CR3, and PR3 or beyond) showed
a major impact on EFS (76% versus 60% versus 50% versus
23%, P ¼ .0002, Figure 2E), with the difference between the
CR2 and CR3 subsets approaching signiﬁcance (P ¼ .06), but
not between those in PR2 and CR3 (P ¼ .9). The effect of
disease status on EFS was also noticed in analysis of the “Bu-
Mel þ BEAM” group (51% in patients in CR2, 30% in PR2, 33%
in CR3, and 13% in PR3 or beyond, P ¼ .01, Figure 2F). In
univariate OS analyses of the entire population, the following
variables were shown to have a signiﬁcant effect: PET at HDC
(P¼ .00004), tumor growth at HDC (P¼ .01), disease status at
HDC (P ¼ .0002), number of prior salvage therapy lines
(P ¼ .04), and number of previous episodes of relapse or
tumor growth (P ¼ .02) (Table 3).
Multivariate Cox models for EFS showed that a treatment
different from Gem-Bu-Mel was independently associated
with worse EFS (HR¼ 2.3, P¼ .0008), alongwith PET-positive
tumors at HDC (HR ¼ 2.2, P ¼ .004) and number of prior
salvage lines (HR ¼ 1.9, P ¼ .008) (Table 4). A different
treatment fromGem-Bu-Mel (HR¼ 2.7, P¼ .0005) and a PET-
positive status (HR ¼ 3.1, P ¼ .0001) were independent
adverse factors for OS (Table 4). The EFS beneﬁt from Gem-
Bu-Mel over “Bu-Mel þ BEAM” was observed within the
subgroups with PET-negative tumors (74% versus 46%,
P ¼ .008, Figure 3A), PET-positive tumors at HDC (42% versus
18%, P ¼ .04, Figure 3B), and 1 prior relapse or PD (76% versus
44%, P ¼ .005, Figure 3C), whereas the differences within the
subgroups with >1 prior relapse did not reach signiﬁcance
(33% versus 28%, P ¼ .2, Figure 3D).
DISCUSSION
Our cohort analysis showed that patients with primary-
refractory or poor-prognosis relapsed HL receiving high-
dose Gem-Bu-Mel showed improved outcome compared
with the cohorts treated with Bu-Mel or BEAM. Despite its
higher prevalence of poor prognosis features, the Gem-Bu-
Mel cohort showed superior EFS and OS.
Gem-Bu-Mel differs from Bu-Mel in the addition of infu-
sional gemcitabine. At standard doses, this agent has clinical
antitumor activity against HL [16,17]. Gem-Bu-Mel exploits
the antitumor proﬁle of gemcitabine, which is highlyTable 4
Cox Proportional Hazard Regression Analyses of the Groups of Refractory HL Patie
EFS
Hazard ratio
High-dose regimen Gem-Bu-Mel 1
Other 2.3 (1.4-3.7)
PET Negative 1
Positive 2.2 (1.2-3.1)
No. prior lines of salvage therapy 1 1
>1 1.1 (.6-2)
B symptoms No 1
Yes 1.1 (.6-2)
CI indicates conﬁdence interval.dependent on both dose and duration of exposure [18-20], by
administering high doses of this drug over prolonged periods
of time at its optimal infusion rate. Themarkedmyelotoxicity
of this administration schedule is circumvented by hemato-
poietic cell support. Gem-Bu-Mel was designed based on the
overriding principles of using a pharmacologically guided
prolonged infusion schedule of gemcitabine in a therapeutic
sequence that would facilitate a synergistic interaction with
busulfan and melphalan based on DNA damage repair inhi-
bition [21]. In addition to this well-establishedmechanism of
synergy, we recently reported that gemcitabine induces
chromatin relaxation, increasing access of busulfan to DNA
and its cytotoxicity in lymphoma cell lines [22].
We observed a major and independent prognostic effect
of PET status at HDC determined prospectively in our
patients. Our study constitutes the largest analysis to date of
pretransplantation PET scans and conﬁrms in a prospective
fashion prior reports. Jabbour et al. reviewed retrospectively
211 patients treated at our institution from 1993 to 2004,
68 of whom had a PET performed before transplantation [6].
This previous study showed that a negative PET and the use
of BEAM, compared with cyclophosphamide-carmustine-
etoposide (CBV), were associated with favorable post-
transplantation outcomes. Moskowitz and colleagues
reviewed retrospectively 153 patients treated with CBV or
cyclophosphamide-carmustine and total lymphoid irradia-
tion between 1994 and 2003 and observed a prognostic
effect of pretransplantation functional imaging, which con-
sisted of PET in 42 patients [7]. Smeltzer et al. described
similar results in their retrospective analysis of 106 patients
treated with BEAM, 46 of whom had pretransplantation PET
scans [8]. Similar observations were made by Arai et al. in
their study of 96 patients treated with gemcitabine-
vinorelbine combined with high-dose CBV, 77 of whom
had pretransplantation PET scans [9]. All these prior studies
and our present report indicate the prognostic signiﬁcance of
pretransplantation PET for patients with HL receiving HDC.
A major challenge remains the approach to patients with
PET-positive tumors after their salvage standard-dose
chemotherapy. Moskowitz et al. evaluated prospectively
this question and observed similar outcomes between
a group of 59 patients in CR2 after salvage ICE and a second
group of 17 patients with persistently positive PET tumors
after second-line therapy who subsequently achieved a CR3
after third-line GND [23]. These patients received CBV IFRT
or cyclophosphamide-carmustine þ total lymphoid irradia-
tion as transplant-conditioning regimens. In contrast, we
observed a trend for better outcomes in our Gem-Bu-Mel
patients in CR2 than in those in CR3 (P ¼ .06), with no
signiﬁcant differences between the Gem-Bu-Mel PR2 and
CR3 subsets (P ¼ .9). Similar observations were made in thents Treated with Gem-Bu-Mel, Bu-Mel, or BEAM
OS
(95% CI P Hazard ratio (95% CI) P
.0008 1 .0005
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Figure 3. EFS comparisons across main patient subgroups. (A) Patients with PET-negative tumors at HDC. (B) Patients with PET-positive tumors. (C) Patients with 1
prior salvage treatment line. (D) Patients with >1 prior salvage treatment line.
Y. Nieto et al. / Biol Blood Marrow Transplant 19 (2013) 410e417416combined “Bu-Mel þ BEAM” group. Different patient pop-
ulations or transplant regimens may account for the differing
results of that study and ours. Although the sequence of
salvage regimens in most of our patients (ESHAP or ICE in
second line and IGEV or GND in third line) appears to be
similar to those used by Moskowitz and colleagues, our
transplant trials were designed to test new HDC combina-
tions and not to address the relative values of different
standard salvage regimens. No patients in either report
received brentuximab vedotin, which is nonecross-resistant
with chemotherapy [24], and may induce metabolic CRs
before HDC in patients with a persistently positive PET scans
after salvage therapy, thus potentially serving as a bridge to
more successful HDC. In addition, brentuximab vedotin may
show to be an effective posttransplantation maintenance
therapy, as it is currently being evaluated.
This analysis was based on intent to treat. The clinical data
of all patients, both those enrolled in the 2 trials and those
treated off protocol, were collected prospectively. Because
the 3 cohorts included in this report were treated at our
institution over a relatively short time period, we consider
the supportive care to be the same for all patients. In fact,
there were no treatment-related deaths in any of the
3 cohorts. However, given the nonrandomized nature of this
comparison, our observations require conﬁrmation in
a randomized trial.
In conclusion, Gem-Bu-Mel improved outcomes
compared with Bu-Mel and BEAM in this analysis ofcontemporary cohorts of patients with refractory or poor-
risk relapsed HL. These observations warrant a randomized
phase III trial of Gem-Bu-Mel in this poor-prognosis
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